The triggering of Fas initially appeared as a promising approach to treat cancer but an agonistic anti-Fas antibody led to fulminant lethal hepatitis upon injection in mice, precluding the use of Fas inducers for a therapeutic purpose in human [10]. This evidence concerns the gene FAS and hepatitis A virus infection.